Search

Displaying results 2551 - 2560 of 10000 in total
  1. Drug

    Navtemadlin

    go.drugbank.com/drugs/DB15299
    Investigational

    Navtemadlin (AMG-232) is under investigation in clinical trial NCT03041688 (MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia

    Synonyms: {(3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-[ (2S)-3 -methyl-1-(propan-2- ylsulfonyl)butan-2-yl]-2-oxopiperidin-3-yl}acetic acidCategories: Heterocyclic Compounds, 1-Ring
  2. Drug

    Ponesimod

    go.drugbank.com/drugs/DB12016
    ApprovedInvestigational

    [A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than [fingolimod]. … Ponesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    Neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB15683
    ApprovedInvestigational

    Synonyms: Neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen, Nimenrix component neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen
  4. Drug

    Mitemcinal

    go.drugbank.com/drugs/DB06587
    Investigational

    Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  5. Drug

    Tenofovir

    go.drugbank.com/drugs/DB14126
    Investigational

    [A37693] In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog.

    Mixtures: EMTRICITABINA 200 MG TENOFOVIR 300 MG, EMTRICITABINA 200 MG TENOFOVIR 300 MGCategories: P-glycoprotein substrates, Heterocyclic Compounds, 2-Ring
  6. Drug

    Mecasermin rinfabate

    go.drugbank.com/drugs/DB14751
    ApprovedInvestigational

    <500 patients worldwide[A176065]. … The binding of IGF-1 to IGFBP-3 is said to extend the half life and reduce the clearance of IGF-1 in patients with growth hormone resistant syndromes and low levels of IGFBP-3 though this may represent

    Synonyms: rhIGF-I/rhIGFBP-3, Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3Categories: Sex Hormones and Insulins
  7. Drug

    CIGB 300

    go.drugbank.com/drugs/DB16464
    Investigational

    CIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma

  8. Drug

    MK-4541

    go.drugbank.com/drugs/DB17016
    Experimental

    MK-4541 is a 4-azasteroid and a selective androgen receptor modulator (SARM). MK-4541 acts as a dual selective SARM and is both a potent androgen receptor antagonist and a 5α-reductase inhibitor.

    Synonyms: 2,2,2-trifluoroethyl N-[(1S,3aS,3bS,5aR,9aR,9bS,11aS)-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,5a,9b,10,11-decahydro-1H-indeno[5,4-f]quinolin-1-yl]carbamate
  9. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    [A262056] ROS1 mutations are one of the defined oncogenic drives of NSCLC, and the solvent-front mutation ROS1 G2032R is responsible for 50 to 60% of [crizotinib]-resistant cases. … Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the

    Synonyms: (3R,6S,)-45-FLUORO-3,6-DIMETHYL-5-OXA-2,8-DIAZA-1(5,3)-PYRAZOLO(1,5-A)PYRIMIDINA-4(1,2)-BENZENANONAPHAN-9-ONE, (7S,13R)-11-Fluoro-7,13-Dimethyl-6,7,13,14-Tetrahydro-1,15-Ethenopyrazolo[4,3-F][1,4,8,10]Benzoxatriazacyclotridecin-4(5H)-OneCategories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Substrates
  10. Drug

    Arundic acid

    go.drugbank.com/drugs/DB05343
    Investigational

    Arundic acid has been investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).

    Synonyms: (2R)-2-propyloctanoic acid